A study published in Biological Psychiatry found that intranasal ketamine conferred an unusually rapid antidepressant effect within 24 hours and was well-tolerated in patients with treatment-resistant major depressive disorder. The results show promise for a new treatment class, targeting the NMDA glutamate receptor.
Researchers found a significant link between exposure to inhaled particulate matter at Ground Zero and the development of obstructive sleep apnea and post-traumatic stress disorder (PTSD) in first responders. The study also showed that those with PTSD had higher levels of inflammation, increasing their risk for cardiovascular disease.
A new stool-based screening test, Cologuard, detected 92% of colorectal cancer and 42% of advanced pre-cancerous lesions, outperforming a commercial occult blood fecal immunochemical test. The non-invasive test allows patients to collect samples at home, increasing the potential for higher cancer screening rates.
A Mount Sinai study reveals that GM-CSF protein production is critical for maintaining immune tolerance in the gut, and its deficiency may lead to increased susceptibility to inflammatory bowel diseases. The research suggests that targeting the GM-CSF axis could be a promising strategy for developing effective treatments for IBD.
Researchers at Mount Sinai Hospital have discovered how the Marburg virus interacts with host protein Keap1, allowing it to live longer and replicate better. This knowledge may lead to the development of targeted therapies to arrest the lethal virus.
A study led by Dr. Sergio A. Lira found that removing gut bacteria reduced polyp formation and inflammation in mice, potentially reducing colorectal cancer risk. The researchers propose a new approach to understanding the interplay between genetic mutations, gut bacteria, and inflammation.
Researchers discovered abnormal molecular signaling pathways that promote chronic kidney disease progression, targeting endothelial mitochondrial oxidative stress and glomerular filtration barrier. New therapeutic targets may prevent or reverse disease, providing hope for millions of Americans affected by kidney disease.
New research reveals that opioid use changes the activity of a specific protein needed for normal brain function, affecting both pain relief and tolerance. The study found that blocking this protein can reduce addiction-related behaviors, but increasing its activity lowers pain relief response and leads to faster morphine tolerance.
A randomized controlled trial found that cognitive behavioral therapy plus hypnosis significantly reduced fatigue in breast cancer patients during and after radiotherapy. The treatment group had less fatigue than 79% of control group patients at the end of radiotherapy, with benefits persisting for up to six months.
Using point-of-care ultrasound for suspected appendicitis in kids has been shown to reduce emergency room length of stay by 46% and avoid unnecessary CT scans. The study found no cases of appendicitis were missed, and surgeons became more comfortable using ultrasound for decision-making.
Researchers identified UHRF1 as a key driver of liver cancer in zebrafish models and human tumors, showing that high levels of UHRF1 can cause tumors to form rapidly. The study suggests that targeting UHRF1 could be an effective approach to halting cancer formation and offers new hope for treatments for hepatocellular carcinoma.
Two large-scale exome studies found a significant role for rare genetic mutations in schizophrenia, contrary to previous assumptions of few 'faulty' genes. The studies established the world's largest database on schizophrenia, providing valuable resources for biomedical research.
Researchers found that adolescent rats exposed to THC experienced molecular changes and increased motivation to self-administer heroin in their adulthood offspring, highlighting potential long-term effects of marijuana use on future generations.
A new nanotherapy breakthrough designed to deliver statin medication directly to inflamed blood vessels could potentially prevent repeat heart attacks and strokes. The technology targets inflammation in blood vessels, reducing the risk of clots and cardiovascular events.
Researchers at Mount Sinai have identified a promising new molecular mechanism for cocaine addiction, implicating the PARP-1 enzyme and Sidekick-1 gene. Chronic cocaine administration increases levels of PARP-1, leading to epigenetic changes that contribute to long-term addiction.
Researchers developed a novel sugar-based tracer contrast agent to aid in the detection of inflamed and vulnerable artery plaques. The new tracer, fluorodeoxymannose (FDM), shows promise in targeting high-risk plaques more specifically than traditional glucose-based tracers.
A new study found that vitamin E delays progression of functional decline by 19% per year, translating into a 6.2-month benefit over placebo. Vitamin E is also easy to purchase and inexpensive, making it a potential treatment strategy for mild-to-moderate Alzheimer's disease.
The Icahn School of Medicine at Mount Sinai is part of a new NIH Stroke Research Network aiming to expedite stroke clinical trials and build expertise in stroke prevention, treatment, and rehabilitation. The school will receive a $1.3 million grant to develop a collaborative research infrastructure.
The grant aims to build a more precise understanding of chronic traumatic encephalopathy and traumatic brain injury in civilians over age 45. Investigators will use extensive resources from an ongoing study of brain aging and conduct analyses of neuropsychology, neuroradiology, neurological, geriatric, and epidemiological aspects.
Mount Sinai researchers found that a drug-resistant H7N9 virus retained its ability to replicate and cause severe illness in humans, even after becoming resistant to Tamiflu. The study suggests that flu viruses can develop drug-resistant mutations without suffering a penalty in terms of their fitness.
New research shows microRNA-128 controls complex functions in the adult brain by adjusting a neuronal signaling pathway. Reducing miR-128 expression led to increased motor activity and fatal epilepsy in mice, while overexpression decreased motor activity and reduced seizure susceptibility.
A new classification system called MOGE(S) has been developed to classify cardiomyopathies, a group of diseases affecting the heart muscle. The system uses a descriptive nomenclature with letters to explain individual patients' cardiomyopathy types and genetic mutations.
A Mount Sinai study found that age-related cognitive decline is linked to energy in synapses in the prefrontal cortex. Estrogen treatment restored synaptic health and improved working memory in rhesus monkeys.
Researchers at the Icahn School of Medicine at Mount Sinai will investigate a new intravenous medication that blocks IL-22, a protein triggering chronic inflammation and epidermal growth abnormalities in eczema. The study aims to develop safer treatments for patients with moderate to severe AD.
Researchers at Mount Sinai found long-term cocaine abuse linked to deficits in parts of the brain monitoring behavior, suggesting targeted treatments based on quantifiable biological abnormalities. The study's findings challenge clinical assumptions about addicted individuals' motivations and behaviors.
Researchers identified critical role of stem cell factor in cardiac repair and regeneration, showing potential clinical benefits of gene transfer to reverse heart damage. The study demonstrated significant improvement in cardiac function and reduced heart muscle cell death.
A multicenter clinical trial found similar patient outcomes one year after surgery for both mitral valve repair and replacement. However, mitral valve replacement was shown to be more durable than repair in preventing recurrence of mitral regurgitation.
A 3-year study in Colombia found that preschoolers participating in a structured curriculum using Sesame Street's materials improved their knowledge of healthy eating and exercise habits by 15-27%. The percentage of children at a healthy weight increased by 13%. Parents' knowledge and attitudes also showed significant improvements.
A single dose of AAV1/SERCA2a gene therapy has long-lasting benefits for advanced heart failure patients, improving heart function status and reducing recurrent cardiovascular events. The study results support the potential use of this gene therapy as a new tool for treating advanced heart failure.
Researchers found that patients with major HAIs after cardiac surgery were nearly twice as likely to be readmitted and incurred costs averaging $40,000 due to treating HAI infections.
A new study published at AHA Scientific Sessions 2013 found that a single dose of stem cell therapy during surgery may improve heart function in LVAD patients. Researchers discovered that 50% of patients who received the treatment could tolerate temporarily turning down their device, compared to 20% of placebo patients.
Arvin Dar, Ph.D., a structural and chemical biologist at Mount Sinai, is awarded $2.5 million to investigate new targets for interrupting the Ras pathway. The goal is to develop new classes of small molecule drugs that impede cancers.
A new gene therapy has shown promising results in reversing heart failure by delivering the SUMO-1 gene directly to the heart. In preclinical testing, the therapy improved cardiac function, reduced heart volumes, and enhanced blood flow compared to other treatments.
A significant link has been found between high levels of exposure to particulate matter by first responders at Ground Zero and the development of kidney damage. Albuminuria, a sign of kidney disease, was significantly higher in those with high exposure levels.
A pilot initiative at Mount Sinai Hospital shows that establishing standardized criteria for calling a palliative care consultation improves the quality of care for patients hospitalized with advanced cancer. This led to increased use of hospice services, lower in-hospital mortality and hospital readmission rates.
Mount Sinai researchers uncover the role of TGFβ2 in determining tumor cell behavior, revealing its potential as a biomarker for dormant cancer cells. The study confirms the 'seed and soil' theory of metastasis, suggesting that conditions within each organ influence tumor cell growth.
A study led by Dr. Pasinetti found that diabetes alters gene expression in the brain, reducing important molecules critical for learning and memory. This epigenetic change increases the risk of developing Alzheimer's disease.
A study by researchers from the Mount Sinai Hospital found that nearly 80% of women who contacted a patient assistance program had their needs met, compared to just 35% of those who did not. Most patients utilized programs for information about adjuvant therapies, psychosocial support, and overcoming practical/financial obstacles.
A team of researchers at Mount Sinai used systems biology and big data analysis to find that combining diabetes drug rosiglitazone with exanatide reduced heart attacks. The approach identifies potential safer combinations, sparking interest in repurposing FDA-approved drugs.
A study led by researchers at Mount Sinai found that individuals with autism were more likely to have gene deletions than those without the disorder, which may contribute to miswiring of brain neurons. The study suggests that these deletions could impact genetic testing and have clinical significance.
A collaborative study between Spain and the Icahn School of Medicine at Mount Sinai found that administering beta-blocker medication to heart attack patients while in transit can significantly reduce heart damage. The study showed metoprolol therapy resulted in smaller infarcts and improved heart contractility.
Researchers have discovered that mucus in the large intestine has anti-inflammatory properties, helping to prevent bacterial-induced inflammation. The study proposes that mucus could be used to treat various diseases, including IBD and cancer, and may even be manufactured for oral administration.
Researchers have discovered a network of genes in stem cells that foster cooperation, which is essential for the development and function of multicellular organisms. The study suggests that understanding this genetic mechanism could lead to new ways to address diseases such as cancer and immune system dysfunction.
Researchers developed a new system to test how viruses interact with cells in the body, revealing insights that will improve viral therapy. The technology allows for the use of real viruses in real environments, enabling scientists to study host targets for antiviral drugs.
Researchers aim to understand and address disparities in CRC screenings for African Americans, with a focus on developing effective intervention strategies. The study seeks to compare the effectiveness of narrative and didactic approaches to educating African Americans about screening.
Researchers at the Seaver Autism Center will test Insulin-Like Growth Factor-1 (IGF-1) in children with Phelan-McDermid Syndrome, a severe type of autism. IGF-1 has shown preclinical promise in reversing nerve cell communication deficits and restoring learning and memory abilities.
Researchers from The Mount Sinai Hospital have developed a new strategy to safely study deadly influenza viruses, including H5N1 bird flu. By harnessing the power of human lung cells, they create 'viral scissors' that can cut these viruses into pieces, preventing effective transmission to humans.
Researchers have developed a new laboratory model to study hepatitis C by infecting monkey stem cells with the virus. The model may lead to new treatments and vaccines for the disease, which affects over three million people in the US.
Researchers found that high dietary sugar acts together with oncogenes to increase insulin sensitivity specifically in tumor cells. A three-drug combination blocking sugar conversion, Ras/Src signaling, and Wingless/Wnt signaling substantially reduced tumor size and progression.
The Mount Sinai Hospital is launching the first-ever genetic testing program in primary care settings to identify genetic risk for kidney disease in patients with hypertension. This $3.7 million grant will provide genomic information to individualize treatment, testing, and monitoring, with a focus on African Americans who are four to ...